Bill Russell

Study sheds light on drug’s impact on diabetes progression

A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

Study drug delays type 1 diabetes in high risk children and adults

Drug delays onset of type 1 diabetes by two years